FDA spanks KVK Tech over impurities in ADHD drug

The FDA has found impurities testing at U.S. generics maker KVK Tech were insufficient. (Image by PublicDomainPictures from Pixabay)

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with an ADHD drug as well as one for weight loss. 

The FDA, in a warning letter posted this week, says, among other problems, KVK Tech of Newtown, Pennsylvania, failed to properly integrate co-eluting peaks during impurity testing of its phentermine HCL capsules, a drug used for weight loss. As a result, the letter says the analysis failed to detect out-of-specification results for at least one lot of the drug.

KVK Tech said even though its methods might underestimate impurities in the drug, the impact was minimal because “the failing batches were ultimately recalled from the market, albeit at a potentially later time.” 

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Generic drugmaker snaps up Lockheed site with big expansion plans

The FDA, unimpressed by this argument, ordered the company to bring in an independent consultant to help it assess its laboratory practices and then put together a plan on how it intends to bring them up to agency expectations. 

The letter also found problems with the plant’s investigation of foreign particles found in a lot of the ADHD drug methylphenidate oral solution. The company said the particles were introduced during filling by wipes used in cleaning equipment. But the FDA said KVK Tech had not adequately investigated the particles and their potential effect on the drug’s quality before releasing the lot. 

In addition to providing the agency with a thorough assessment of how it investigates deviations, the FDA asked for an independent assessment of four years worth of manufacturing records “to determine if manufacturing events” that should have been uncovered had been missed. 

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.